Switch to:
Also traded in: Brazil, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.06
DHR's Cash-to-Debt is ranked lower than
95% of the 244 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.13 vs. DHR: 0.06 )
Ranked among companies with meaningful Cash-to-Debt only.
DHR' s Cash-to-Debt Range Over the Past 10 Years
Min: 0  Med: 0.16 Max: 1.33
Current: 0.06
0
1.33
Equity-to-Asset 0.55
DHR's Equity-to-Asset is ranked lower than
61% of the 228 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. DHR: 0.55 )
Ranked among companies with meaningful Equity-to-Asset only.
DHR' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.16  Med: 0.51 Max: 0.67
Current: 0.55
0.16
0.67
Debt-to-Equity 0.43
DHR's Debt-to-Equity is ranked lower than
60% of the 150 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.35 vs. DHR: 0.43 )
Ranked among companies with meaningful Debt-to-Equity only.
DHR' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.13  Med: 0.36 Max: 3.82
Current: 0.43
0.13
3.82
Debt-to-EBITDA 2.70
DHR's Debt-to-EBITDA is ranked lower than
68% of the 111 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.62 vs. DHR: 2.70 )
Ranked among companies with meaningful Debt-to-EBITDA only.
DHR' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.79  Med: 1.44 Max: 4.21
Current: 2.7
0.79
4.21
Interest Coverage 18.30
DHR's Interest Coverage is ranked lower than
58% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 60.25 vs. DHR: 18.30 )
Ranked among companies with meaningful Interest Coverage only.
DHR' s Interest Coverage Range Over the Past 10 Years
Min: 12.58  Med: 16.69 Max: 22.1
Current: 18.3
12.58
22.1
Piotroski F-Score: 7
Altman Z-Score: 3.16
Beneish M-Score: -2.56
WACC vs ROIC
7.00%
7.28%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 15.73
DHR's Operating Margin % is ranked higher than
85% of the 229 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. DHR: 15.73 )
Ranked among companies with meaningful Operating Margin % only.
DHR' s Operating Margin % Range Over the Past 10 Years
Min: 13.79  Med: 16.08 Max: 17.33
Current: 15.73
13.79
17.33
Net Margin % 13.36
DHR's Net Margin % is ranked higher than
86% of the 228 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.44 vs. DHR: 13.36 )
Ranked among companies with meaningful Net Margin % only.
DHR' s Net Margin % Range Over the Past 10 Years
Min: 10.3  Med: 13.9 Max: 23.26
Current: 13.36
10.3
23.26
ROE % 9.93
DHR's ROE % is ranked higher than
67% of the 222 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.01 vs. DHR: 9.93 )
Ranked among companies with meaningful ROE % only.
DHR' s ROE % Range Over the Past 10 Years
Min: 9.93  Med: 13.64 Max: 17.42
Current: 9.93
9.93
17.42
ROA % 5.33
DHR's ROA % is ranked higher than
71% of the 244 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.54 vs. DHR: 5.33 )
Ranked among companies with meaningful ROA % only.
DHR' s ROA % Range Over the Past 10 Years
Min: 5.33  Med: 7.75 Max: 9.03
Current: 5.33
5.33
9.03
ROC (Joel Greenblatt) % 72.07
DHR's ROC (Joel Greenblatt) % is ranked higher than
89% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.64 vs. DHR: 72.07 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
DHR' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 59.73  Med: 82.44 Max: 118.82
Current: 72.07
59.73
118.82
3-Year Revenue Growth Rate -2.10
DHR's 3-Year Revenue Growth Rate is ranked lower than
68% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.10 vs. DHR: -2.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
DHR' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -9.7  Med: 9.7 Max: 47.6
Current: -2.1
-9.7
47.6
3-Year EBITDA Growth Rate -3.30
DHR's 3-Year EBITDA Growth Rate is ranked lower than
67% of the 173 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.90 vs. DHR: -3.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
DHR' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -19  Med: 11.7 Max: 51.5
Current: -3.3
-19
51.5
3-Year EPS without NRI Growth Rate -5.50
DHR's 3-Year EPS without NRI Growth Rate is ranked lower than
57% of the 159 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.10 vs. DHR: -5.50 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
DHR' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -33.7  Med: 14.7 Max: 92
Current: -5.5
-33.7
92
GuruFocus has detected 4 Warning Signs with Danaher Corp DHR.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» DHR's 30-Y Financials

Financials (Next Earnings Date: 2018-01-31)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

DHR Guru Trades in Q3 2016

George Soros 7,970 sh (New)
Robert Olstein 47,000 sh (New)
Joel Greenblatt 596,095 sh (New)
Caxton Associates 120,000 sh (New)
Louis Moore Bacon 38,781 sh (+949.27%)
Paul Tudor Jones 65,140 sh (+499.87%)
Ray Dalio 75,600 sh (+245.44%)
Steven Cohen 338,100 sh (+126.36%)
Jim Simons 857,000 sh (+60.49%)
Ruane Cunniff 1,821,908 sh (+17.86%)
Daniel Loeb 4,500,000 sh (+16.88%)
First Eagle Investment 2,450,049 sh (+5.39%)
Ken Fisher 5,760 sh (+1.11%)
Chuck Akre 1,500,000 sh (unchged)
John Hussman 30,000 sh (unchged)
Mairs and Power Sold Out
Manning & Napier Advisors, Inc Sold Out
Pioneer Investments Sold Out
Murray Stahl 36,171 sh (-0.08%)
John Griffin 2,246,000 sh (-3.14%)
Dodge & Cox 5,715,408 sh (-14.11%)
Mario Gabelli 10,751 sh (-50.57%)
Jeremy Grantham 3,826 sh (-60.63%)
John Burbank 40,000 sh (-70.64%)
» More
Q4 2016

DHR Guru Trades in Q4 2016

Paul Tudor Jones 484,432 sh (+643.68%)
Steven Cohen 663,300 sh (+96.18%)
Jim Simons 1,522,100 sh (+77.61%)
First Eagle Investment 3,157,097 sh (+28.86%)
Robert Olstein 55,000 sh (+17.02%)
Chuck Akre 1,655,300 sh (+10.35%)
Mario Gabelli 11,196 sh (+4.14%)
John Hussman 30,000 sh (unchged)
George Soros Sold Out
Caxton Associates Sold Out
Ray Dalio Sold Out
John Burbank Sold Out
Murray Stahl 35,587 sh (-1.61%)
Ruane Cunniff 1,733,275 sh (-4.86%)
Dodge & Cox 5,221,273 sh (-8.65%)
Ken Fisher 5,127 sh (-10.99%)
Jeremy Grantham 3,226 sh (-15.68%)
John Griffin 1,760,000 sh (-21.64%)
Daniel Loeb 3,250,000 sh (-27.78%)
Joel Greenblatt 420,700 sh (-29.42%)
» More
Q1 2017

DHR Guru Trades in Q1 2017

Caxton Associates 7,300 sh (New)
Ray Dalio 16,638 sh (New)
Louis Moore Bacon 125,201 sh (+222.84%)
Robert Olstein 65,000 sh (+18.18%)
Ken Fisher 5,224 sh (+1.89%)
Chuck Akre 1,655,300 sh (unchged)
John Hussman 30,000 sh (unchged)
John Griffin 1,760,000 sh (unchged)
Jeremy Grantham Sold Out
Steven Cohen Sold Out
Paul Tudor Jones Sold Out
Dodge & Cox 5,099,223 sh (-2.34%)
Ruane Cunniff 1,664,622 sh (-3.96%)
Murray Stahl 34,135 sh (-4.08%)
Jim Simons 1,459,300 sh (-4.13%)
Mario Gabelli 10,696 sh (-4.47%)
Daniel Loeb 3,100,000 sh (-4.62%)
First Eagle Investment 2,623,552 sh (-16.90%)
Joel Greenblatt 269,309 sh (-35.99%)
» More
Q2 2017

DHR Guru Trades in Q2 2017

Paul Tudor Jones 30,918 sh (New)
Steven Cohen 697,114 sh (New)
Louis Moore Bacon 214,900 sh (+71.64%)
Jim Simons 1,697,400 sh (+16.32%)
First Eagle Investment 2,925,603 sh (+11.51%)
Daniel Loeb 3,300,000 sh (+6.45%)
Ken Fisher 5,423 sh (+3.81%)
Dodge & Cox 5,250,773 sh (+2.97%)
Robert Olstein 65,000 sh (unchged)
Chuck Akre 1,655,300 sh (unchged)
John Hussman Sold Out
Ray Dalio Sold Out
Joel Greenblatt Sold Out
Mario Gabelli 10,616 sh (-0.75%)
Ruane Cunniff 1,648,054 sh (-1.00%)
Murray Stahl 33,664 sh (-1.38%)
Caxton Associates 7,100 sh (-2.74%)
John Griffin 1,487,700 sh (-15.47%)
» More
» Details

Insider Trades

Latest Guru Trades with DHR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Dodge & Cox 2017-06-30 Add 2.97%0.01%$81.7 - $86.84 $ 90.797%5,250,773
First Eagle Investment 2017-06-30 Add 11.51%0.06%$81.7 - $86.84 $ 90.797%2,925,603
Ruane Cunniff 2017-06-30 Reduce -1.00%0.01%$81.7 - $86.84 $ 90.797%1,648,054
Mario Gabelli 2017-06-30 Reduce -0.75%$81.7 - $86.84 $ 90.797%10,616
Ken Fisher 2017-06-30 Add 3.81%$81.7 - $86.84 $ 90.798%5,423
Joel Greenblatt 2017-06-30 Sold Out 0.29%$81.7 - $86.84 $ 90.797%0
Dodge & Cox 2017-03-31 Reduce -2.34%0.01%$78.78 - $87.76 $ 90.798%5,099,223
First Eagle Investment 2017-03-31 Reduce -16.90%0.11%$78.78 - $87.76 $ 90.798%2,623,552
Ruane Cunniff 2017-03-31 Reduce -3.96%0.05%$78.78 - $87.76 $ 90.798%1,664,622
Joel Greenblatt 2017-03-31 Reduce -35.99%0.15%$78.78 - $87.76 $ 90.798%269,309
Robert Olstein 2017-03-31 Add 18.18%0.11%$78.78 - $87.76 $ 90.798%65,000
Mario Gabelli 2017-03-31 Reduce -4.47%$78.78 - $87.76 $ 90.798%10,696
Ken Fisher 2017-03-31 Add 1.89%$78.78 - $87.76 $ 90.798%5,224
Dodge & Cox 2016-12-31 Reduce -8.65%0.04%$75.86 - $80.94 $ 90.7916%5,221,273
First Eagle Investment 2016-12-31 Add 28.86%0.14%$75.86 - $80.94 $ 90.7916%3,157,097
Ruane Cunniff 2016-12-31 Reduce -4.86%0.07%$75.86 - $80.94 $ 90.7916%1,733,275
Chuck Akre 2016-12-31 Add 10.35%0.22%$75.86 - $80.94 $ 90.7916%1,655,300
Joel Greenblatt 2016-12-31 Reduce -29.42%0.18%$75.86 - $80.94 $ 90.7916%420,700
Robert Olstein 2016-12-31 Add 17.02%0.08%$75.86 - $80.94 $ 90.7916%55,000
Mario Gabelli 2016-12-31 Add 4.14%$75.86 - $80.94 $ 90.7916%11,196
Ken Fisher 2016-12-31 Reduce -10.99%$75.86 - $80.94 $ 90.7916%5,127
George Soros 2016-12-31 Sold Out 0.02%$75.86 - $80.94 $ 90.7916%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}